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Introduction {#jcsm12411-sec-0001}
============

Approximately one‐third of older adults fall at least once a year[1](#jcsm12411-bib-0001){ref-type="ref"} and a median of 4.1% of falls results in fractures.[2](#jcsm12411-bib-0002){ref-type="ref"} Falls are associated with physical disability, functional impairment, dependency in activities of daily living, institutionalization, increased morbidity, and mortality.[3](#jcsm12411-bib-0003){ref-type="ref"}, [4](#jcsm12411-bib-0004){ref-type="ref"} A number of risk factors have been found to predispose older adults to falls. These include old age, female sex, fear of falling, impaired cognition, mobility, and gait.[5](#jcsm12411-bib-0005){ref-type="ref"}, [6](#jcsm12411-bib-0006){ref-type="ref"}, [7](#jcsm12411-bib-0007){ref-type="ref"}, [8](#jcsm12411-bib-0008){ref-type="ref"} One of the potentially modifiable risk factors is sarcopenia, that is, age‐related low skeletal muscle mass, strength, and physical performance.[9](#jcsm12411-bib-0009){ref-type="ref"}

Sarcopenia is prevalent between 2% and 37% in community‐dwelling older adults, depending on the sarcopenia definition applied[10](#jcsm12411-bib-0010){ref-type="ref"}, [11](#jcsm12411-bib-0011){ref-type="ref"}, [12](#jcsm12411-bib-0012){ref-type="ref"} and associated with decreased mobility, impaired standing balance, functional decline, hospitalization, and mortality.[13](#jcsm12411-bib-0013){ref-type="ref"}, [14](#jcsm12411-bib-0014){ref-type="ref"}, [15](#jcsm12411-bib-0015){ref-type="ref"} Interventions to prevent and treat sarcopenia have been shown to be effective in increasing muscle mass, strength, and physical performance,[9](#jcsm12411-bib-0009){ref-type="ref"}, [16](#jcsm12411-bib-0016){ref-type="ref"} although it is not proven yet that this leads to a decrease of falls and fractures.

The aim of this systematic review and meta‐analysis was to evaluate whether sarcopenic individuals have a higher risk of falls and fractures compared with non‐sarcopenic individuals and whether this association is influenced by study design, population, sex, sarcopenia definition, continent, or study quality.

Methods {#jcsm12411-sec-0002}
=======

Data sources and searches {#jcsm12411-sec-0003}
-------------------------

The protocol of the systematic review was registered at PROSPERO International prospective register of systematic reviews: CRD42017068485. The systematic review was conducted according to the PRISMA standards.[17](#jcsm12411-bib-0017){ref-type="ref"} A systematic search was performed by a librarian in four electronic databases, that is, MEDLINE, EMBASE, Cochrane Central, and CINAHL from date of inception to 1 May 2018 ([Online Resource S1](#jcsm12411-supitem-0001){ref-type="supplementary-material"}). The search included the keywords 'sarcopenia', 'falls', 'fractures', and synonyms. The reference section of each included article was also used to identify additional related research studies.

Study selection {#jcsm12411-sec-0004}
---------------

The studies obtained using the search strategy were assessed for eligibility independently by two authors (S. S. Y. Y. and V. K. P.) by screening titles and abstracts. Subsequently, the full‐text articles of potentially relevant studies were screened independently by two reviewers (S. S. Y. Y. and V. K. P.). A third reviewer (E. M. R.) resolved any disagreements between the authors regarding the eligibility by discussion and reaching a consensus. Studies were included in the systematic review when the following inclusion criteria were met: published in English; mean or median age of ≥65 years or with subgroup analysis in those aged ≥65 years; diagnosis of sarcopenia using any definition used by the original studies\' authors; and at least one of the following outcomes: falls and/or fractures. No restriction regarding study population was applied. Studies were excluded if they did not contain primary data (conference abstracts, reviews, letters to the editor, and case reports with \<5 cases). Studies were excluded if no comparison group was included; that is, all individuals suffered from falls, fractures, or sarcopenia. If studies used data from the same cohort,[18](#jcsm12411-bib-0018){ref-type="ref"}, [19](#jcsm12411-bib-0019){ref-type="ref"} the studies with the largest sample size were included.[18](#jcsm12411-bib-0018){ref-type="ref"}

Data extraction and quality assessment {#jcsm12411-sec-0005}
--------------------------------------

The following variables were extracted independently by two reviewers (S. S. Y. Y. and V. K. P.) from the included studies: author, year of publication, total number of individuals included in the study, mean/median age of individuals, percentage of females, population, continent, prevalence of falls, study design of falls outcome, prevalence of fractures, study design of fractures outcome, applied definition(s) of sarcopenia, prevalence of sarcopenia, assessment method of muscle mass, cut‐off point of muscle mass, assessment method of muscle strength, cut‐off point of muscle strength, assessment method of physical performance, and cut‐off point of physical performance.

Risk of bias of the included studies was assessed independently by two reviewers (S. S. Y. Y. and V. K. P.) using the Newcastle Ottawa Scale (NOS)[20](#jcsm12411-bib-0020){ref-type="ref"}, [21](#jcsm12411-bib-0021){ref-type="ref"} for case--control and cohort studies and a modified version of the NOS for cross‐sectional studies. A system of points was given to the eligible categories: (i) selection of the study population, (ii) comparability, and (iii) description of the outcome ([Online Resource S2](#jcsm12411-supitem-0002){ref-type="supplementary-material"}). A study was given a maximum of one point in each item within the Selection and Outcome categories and a maximum of two points was given for the Comparability category. The scale scores varied depending on the study design. For case--control and cohort studies, it ranged from 0 to 9 points with ≥7 points classified as high quality.[20](#jcsm12411-bib-0020){ref-type="ref"} For cross‐sectional studies, it ranged from 0 to 7 points. Because a modified version of NOS was used and there was no cut‐off available from the literature, a median of ≥4 points was considered as high quality for cross‐sectional studies.[22](#jcsm12411-bib-0022){ref-type="ref"}, [23](#jcsm12411-bib-0023){ref-type="ref"}

Data synthesis and analysis {#jcsm12411-sec-0006}
---------------------------

A meta‐analysis was performed stratified for falls and fractures, using a random‐effects model because of assumed heterogeneity between the studies. Studies were excluded from the meta‐analysis if an odds ratio (OR) could not be calculated because of insufficient data or confidence intervals (CIs) were not given. When both crude and adjusted ORs were reported, adjusted ORs were used. When the studies only reported ORs stratified by sex, the overall OR was calculated from a two‐by‐two table including the total number of sarcopenic and non‐sarcopenic individuals with falls/fractures. Sarcopenia definitions differ in their composition including muscle mass, muscle strength, and physical performance, and applying different definitions has an impact on the prevalence of sarcopenia.[11](#jcsm12411-bib-0011){ref-type="ref"}, [12](#jcsm12411-bib-0012){ref-type="ref"} Some definitions are based on low muscle mass alone: Baumgartner *et al*.,[24](#jcsm12411-bib-0024){ref-type="ref"}, [25](#jcsm12411-bib-0025){ref-type="ref"}, [26](#jcsm12411-bib-0026){ref-type="ref"}, [27](#jcsm12411-bib-0027){ref-type="ref"}, [28](#jcsm12411-bib-0028){ref-type="ref"} Delmonico *et al*.,[24](#jcsm12411-bib-0024){ref-type="ref"}, [27](#jcsm12411-bib-0027){ref-type="ref"} Newman *et al*.,[25](#jcsm12411-bib-0025){ref-type="ref"} Cheng *et al*.,[29](#jcsm12411-bib-0029){ref-type="ref"} Scott *et al*.,[28](#jcsm12411-bib-0028){ref-type="ref"} Sanada *et al*.,[30](#jcsm12411-bib-0030){ref-type="ref"}, [31](#jcsm12411-bib-0031){ref-type="ref"} Levine and Crimmins,[28](#jcsm12411-bib-0028){ref-type="ref"} and Bouchard *et al*..[28](#jcsm12411-bib-0028){ref-type="ref"} Other definitions are based on both low muscle mass and low muscle strength/physical performance: European Working Group on Sarcopenia in Older People (EWGSOP),[24](#jcsm12411-bib-0024){ref-type="ref"}, [25](#jcsm12411-bib-0025){ref-type="ref"}, [28](#jcsm12411-bib-0028){ref-type="ref"}, [32](#jcsm12411-bib-0032){ref-type="ref"}, [33](#jcsm12411-bib-0033){ref-type="ref"}, [34](#jcsm12411-bib-0034){ref-type="ref"}, [35](#jcsm12411-bib-0035){ref-type="ref"}, [36](#jcsm12411-bib-0036){ref-type="ref"}, [37](#jcsm12411-bib-0037){ref-type="ref"}, [38](#jcsm12411-bib-0038){ref-type="ref"}, [39](#jcsm12411-bib-0039){ref-type="ref"}, [40](#jcsm12411-bib-0040){ref-type="ref"}, [41](#jcsm12411-bib-0041){ref-type="ref"}, [42](#jcsm12411-bib-0042){ref-type="ref"}, [43](#jcsm12411-bib-0043){ref-type="ref"}, [44](#jcsm12411-bib-0044){ref-type="ref"}, [45](#jcsm12411-bib-0045){ref-type="ref"}, [46](#jcsm12411-bib-0046){ref-type="ref"}, [47](#jcsm12411-bib-0047){ref-type="ref"}, [48](#jcsm12411-bib-0048){ref-type="ref"}, [49](#jcsm12411-bib-0049){ref-type="ref"}, [50](#jcsm12411-bib-0050){ref-type="ref"}, [51](#jcsm12411-bib-0051){ref-type="ref"}, [52](#jcsm12411-bib-0052){ref-type="ref"} Asian Working Group for Sarcopenia (AWGS),[18](#jcsm12411-bib-0018){ref-type="ref"}, [51](#jcsm12411-bib-0051){ref-type="ref"}, [53](#jcsm12411-bib-0053){ref-type="ref"}, [54](#jcsm12411-bib-0054){ref-type="ref"} Foundation for the National Institutes of Health (FNIH),[24](#jcsm12411-bib-0024){ref-type="ref"}, [25](#jcsm12411-bib-0025){ref-type="ref"}, [27](#jcsm12411-bib-0027){ref-type="ref"}, [35](#jcsm12411-bib-0035){ref-type="ref"}, [44](#jcsm12411-bib-0044){ref-type="ref"}, [46](#jcsm12411-bib-0046){ref-type="ref"}, [55](#jcsm12411-bib-0055){ref-type="ref"} International Working Group on Sarcopenia (IWGS),[24](#jcsm12411-bib-0024){ref-type="ref"}, [25](#jcsm12411-bib-0025){ref-type="ref"}, [27](#jcsm12411-bib-0027){ref-type="ref"}, [35](#jcsm12411-bib-0035){ref-type="ref"} Society for Sarcopenia, Cachexia, and Wasting Disorders (SCWD),[24](#jcsm12411-bib-0024){ref-type="ref"}, [27](#jcsm12411-bib-0027){ref-type="ref"} and ESPEN Special Interest Group on 'cachexia‐anorexia in chronic wasting diseases' and 'nutrition in geriatrics'.[24](#jcsm12411-bib-0024){ref-type="ref"} In cases where studies applied multiple sarcopenia definitions, results based on the EWGSOP definition[52](#jcsm12411-bib-0052){ref-type="ref"} were prioritized over the Baumgartner definition[56](#jcsm12411-bib-0056){ref-type="ref"} and other definitions.[57](#jcsm12411-bib-0057){ref-type="ref"}, [58](#jcsm12411-bib-0058){ref-type="ref"}, [59](#jcsm12411-bib-0059){ref-type="ref"}, [60](#jcsm12411-bib-0060){ref-type="ref"}, [61](#jcsm12411-bib-0061){ref-type="ref"}, [62](#jcsm12411-bib-0062){ref-type="ref"}, [63](#jcsm12411-bib-0063){ref-type="ref"}, [64](#jcsm12411-bib-0064){ref-type="ref"}, [65](#jcsm12411-bib-0065){ref-type="ref"}, [66](#jcsm12411-bib-0066){ref-type="ref"}, [67](#jcsm12411-bib-0067){ref-type="ref"}, [68](#jcsm12411-bib-0068){ref-type="ref"}

Forest plots were used to visualize the results. Heterogeneity between the studies in effect measures were assessed using the *I* ^2^ statistic. *I* ^2^ values greater than 25% were considered to reflect low heterogeneity, 50% moderate, and 75% high heterogeneity.[69](#jcsm12411-bib-0069){ref-type="ref"} Subgroup analyses were performed regarding study design, population, sex, sarcopenia definition, continent, and study quality. We contacted 17 authors of studies to obtain the data needed to compute ORs when the study did not report ORs stratified by sex. Ten authors responded, which allowed us to include these studies in the subgroup analysis.[27](#jcsm12411-bib-0027){ref-type="ref"}, [28](#jcsm12411-bib-0028){ref-type="ref"}, [32](#jcsm12411-bib-0032){ref-type="ref"}, [33](#jcsm12411-bib-0033){ref-type="ref"}, [40](#jcsm12411-bib-0040){ref-type="ref"}, [41](#jcsm12411-bib-0041){ref-type="ref"}, [42](#jcsm12411-bib-0042){ref-type="ref"}, [43](#jcsm12411-bib-0043){ref-type="ref"}, [49](#jcsm12411-bib-0049){ref-type="ref"}, [54](#jcsm12411-bib-0054){ref-type="ref"} Funnel plots of log OR against its standard error were plotted to visually evaluate publication bias, while Egger\'s regression test[70](#jcsm12411-bib-0070){ref-type="ref"} and Begg\'s test[71](#jcsm12411-bib-0071){ref-type="ref"} were used to statistically evaluate publication bias. Comprehensive Meta‐Analysis (CMA version 2.0; Biostat Inc., Engle‐wood, NJ) was used to produce pooled estimates and forest plots. *P*‐values \< 0.05 were considered statistically significant (two‐sided).

Results {#jcsm12411-sec-0007}
=======

Search results {#jcsm12411-sec-0008}
--------------

[Online Resource S3](#jcsm12411-supitem-0003){ref-type="supplementary-material"} shows the flow chart of the study selection. A total of 4129 studies were retrieved through electronic database searches. After removal of duplicates, 2771 studies were identified for title and abstract screening. Review of the titles and abstracts yielded 241 relevant studies for full‐text screening. Thirty‐six studies met all inclusion criteria and were included in this review.[18](#jcsm12411-bib-0018){ref-type="ref"}, [24](#jcsm12411-bib-0024){ref-type="ref"}, [25](#jcsm12411-bib-0025){ref-type="ref"}, [26](#jcsm12411-bib-0026){ref-type="ref"}, [27](#jcsm12411-bib-0027){ref-type="ref"}, [28](#jcsm12411-bib-0028){ref-type="ref"}, [29](#jcsm12411-bib-0029){ref-type="ref"}, [30](#jcsm12411-bib-0030){ref-type="ref"}, [31](#jcsm12411-bib-0031){ref-type="ref"}, [32](#jcsm12411-bib-0032){ref-type="ref"}, [33](#jcsm12411-bib-0033){ref-type="ref"}, [34](#jcsm12411-bib-0034){ref-type="ref"}, [35](#jcsm12411-bib-0035){ref-type="ref"}, [36](#jcsm12411-bib-0036){ref-type="ref"}, [37](#jcsm12411-bib-0037){ref-type="ref"}, [38](#jcsm12411-bib-0038){ref-type="ref"}, [39](#jcsm12411-bib-0039){ref-type="ref"}, [40](#jcsm12411-bib-0040){ref-type="ref"}, [41](#jcsm12411-bib-0041){ref-type="ref"}, [42](#jcsm12411-bib-0042){ref-type="ref"}, [43](#jcsm12411-bib-0043){ref-type="ref"}, [44](#jcsm12411-bib-0044){ref-type="ref"}, [45](#jcsm12411-bib-0045){ref-type="ref"}, [46](#jcsm12411-bib-0046){ref-type="ref"}, [47](#jcsm12411-bib-0047){ref-type="ref"}, [48](#jcsm12411-bib-0048){ref-type="ref"}, [49](#jcsm12411-bib-0049){ref-type="ref"}, [50](#jcsm12411-bib-0050){ref-type="ref"}, [51](#jcsm12411-bib-0051){ref-type="ref"}, [52](#jcsm12411-bib-0052){ref-type="ref"}, [54](#jcsm12411-bib-0054){ref-type="ref"}, [55](#jcsm12411-bib-0055){ref-type="ref"}, [72](#jcsm12411-bib-0072){ref-type="ref"}, [73](#jcsm12411-bib-0073){ref-type="ref"}, [74](#jcsm12411-bib-0074){ref-type="ref"}, [75](#jcsm12411-bib-0075){ref-type="ref"} A total of 33 studies were included in the meta‐analysis; four of them presented data for both falls and fractures, leaving 20 studies included in the meta‐analysis for falls[24](#jcsm12411-bib-0024){ref-type="ref"}, [26](#jcsm12411-bib-0026){ref-type="ref"}, [28](#jcsm12411-bib-0028){ref-type="ref"}, [32](#jcsm12411-bib-0032){ref-type="ref"}, [33](#jcsm12411-bib-0033){ref-type="ref"}, [34](#jcsm12411-bib-0034){ref-type="ref"}, [35](#jcsm12411-bib-0035){ref-type="ref"}, [36](#jcsm12411-bib-0036){ref-type="ref"}, [40](#jcsm12411-bib-0040){ref-type="ref"}, [41](#jcsm12411-bib-0041){ref-type="ref"}, [42](#jcsm12411-bib-0042){ref-type="ref"}, [43](#jcsm12411-bib-0043){ref-type="ref"}, [44](#jcsm12411-bib-0044){ref-type="ref"}, [48](#jcsm12411-bib-0048){ref-type="ref"}, [49](#jcsm12411-bib-0049){ref-type="ref"}, [50](#jcsm12411-bib-0050){ref-type="ref"}, [72](#jcsm12411-bib-0072){ref-type="ref"}, [73](#jcsm12411-bib-0073){ref-type="ref"}, [74](#jcsm12411-bib-0074){ref-type="ref"}, [75](#jcsm12411-bib-0075){ref-type="ref"} and 17 studies for fractures.[18](#jcsm12411-bib-0018){ref-type="ref"}, [27](#jcsm12411-bib-0027){ref-type="ref"}, [29](#jcsm12411-bib-0029){ref-type="ref"}, [30](#jcsm12411-bib-0030){ref-type="ref"}, [31](#jcsm12411-bib-0031){ref-type="ref"}, [34](#jcsm12411-bib-0034){ref-type="ref"}, [35](#jcsm12411-bib-0035){ref-type="ref"}, [38](#jcsm12411-bib-0038){ref-type="ref"}, [39](#jcsm12411-bib-0039){ref-type="ref"}, [42](#jcsm12411-bib-0042){ref-type="ref"}, [46](#jcsm12411-bib-0046){ref-type="ref"}, [47](#jcsm12411-bib-0047){ref-type="ref"}, [49](#jcsm12411-bib-0049){ref-type="ref"}, [51](#jcsm12411-bib-0051){ref-type="ref"}, [54](#jcsm12411-bib-0054){ref-type="ref"}, [55](#jcsm12411-bib-0055){ref-type="ref"}, [73](#jcsm12411-bib-0073){ref-type="ref"}

Study characteristics {#jcsm12411-sec-0009}
---------------------

*Table* [1](#jcsm12411-tbl-0001){ref-type="table"} shows the study characteristics of the included studies. A total of 52 838 individuals (48.8% females) with a mean age of the study populations ranging from 65.0 to 86.7 years were included, and sample sizes ranged from 58 to 6,658 individuals. Study populations included community‐dwelling individuals (22 studies),[18](#jcsm12411-bib-0018){ref-type="ref"}, [24](#jcsm12411-bib-0024){ref-type="ref"}, [25](#jcsm12411-bib-0025){ref-type="ref"}, [26](#jcsm12411-bib-0026){ref-type="ref"}, [27](#jcsm12411-bib-0027){ref-type="ref"}, [28](#jcsm12411-bib-0028){ref-type="ref"}, [34](#jcsm12411-bib-0034){ref-type="ref"}, [35](#jcsm12411-bib-0035){ref-type="ref"}, [36](#jcsm12411-bib-0036){ref-type="ref"}, [40](#jcsm12411-bib-0040){ref-type="ref"}, [41](#jcsm12411-bib-0041){ref-type="ref"}, [42](#jcsm12411-bib-0042){ref-type="ref"}, [44](#jcsm12411-bib-0044){ref-type="ref"}, [45](#jcsm12411-bib-0045){ref-type="ref"}, [46](#jcsm12411-bib-0046){ref-type="ref"}, [48](#jcsm12411-bib-0048){ref-type="ref"}, [49](#jcsm12411-bib-0049){ref-type="ref"}, [50](#jcsm12411-bib-0050){ref-type="ref"}, [51](#jcsm12411-bib-0051){ref-type="ref"}, [72](#jcsm12411-bib-0072){ref-type="ref"}, [73](#jcsm12411-bib-0073){ref-type="ref"}, [75](#jcsm12411-bib-0075){ref-type="ref"} hospitalized patients (3 studies),[43](#jcsm12411-bib-0043){ref-type="ref"}, [47](#jcsm12411-bib-0047){ref-type="ref"}, [54](#jcsm12411-bib-0054){ref-type="ref"} outpatients (4 studies),[32](#jcsm12411-bib-0032){ref-type="ref"}, [38](#jcsm12411-bib-0038){ref-type="ref"}, [39](#jcsm12411-bib-0039){ref-type="ref"}, [55](#jcsm12411-bib-0055){ref-type="ref"} and nursing home residents (3 studies).[33](#jcsm12411-bib-0033){ref-type="ref"}, [37](#jcsm12411-bib-0037){ref-type="ref"}, [74](#jcsm12411-bib-0074){ref-type="ref"} Four studies included a combined group of hospitalized patients with fractures and community‐dwelling individuals without fractures.[29](#jcsm12411-bib-0029){ref-type="ref"}, [30](#jcsm12411-bib-0030){ref-type="ref"}, [31](#jcsm12411-bib-0031){ref-type="ref"}, [51](#jcsm12411-bib-0051){ref-type="ref"} Two studies reported retrospective data,[31](#jcsm12411-bib-0031){ref-type="ref"}, [55](#jcsm12411-bib-0055){ref-type="ref"} 20 studies were cross‐sectional,[26](#jcsm12411-bib-0026){ref-type="ref"}, [29](#jcsm12411-bib-0029){ref-type="ref"}, [30](#jcsm12411-bib-0030){ref-type="ref"}, [32](#jcsm12411-bib-0032){ref-type="ref"}, [35](#jcsm12411-bib-0035){ref-type="ref"}, [36](#jcsm12411-bib-0036){ref-type="ref"}, [38](#jcsm12411-bib-0038){ref-type="ref"}, [39](#jcsm12411-bib-0039){ref-type="ref"}, [41](#jcsm12411-bib-0041){ref-type="ref"}, [42](#jcsm12411-bib-0042){ref-type="ref"}, [43](#jcsm12411-bib-0043){ref-type="ref"}, [44](#jcsm12411-bib-0044){ref-type="ref"}, [48](#jcsm12411-bib-0048){ref-type="ref"}, [49](#jcsm12411-bib-0049){ref-type="ref"}, [50](#jcsm12411-bib-0050){ref-type="ref"}, [51](#jcsm12411-bib-0051){ref-type="ref"}, [54](#jcsm12411-bib-0054){ref-type="ref"}, [72](#jcsm12411-bib-0072){ref-type="ref"}, [73](#jcsm12411-bib-0073){ref-type="ref"}, [75](#jcsm12411-bib-0075){ref-type="ref"} 13 studies were prospective,[18](#jcsm12411-bib-0018){ref-type="ref"}, [25](#jcsm12411-bib-0025){ref-type="ref"}, [27](#jcsm12411-bib-0027){ref-type="ref"}, [28](#jcsm12411-bib-0028){ref-type="ref"}, [33](#jcsm12411-bib-0033){ref-type="ref"}, [34](#jcsm12411-bib-0034){ref-type="ref"}, [37](#jcsm12411-bib-0037){ref-type="ref"}, [40](#jcsm12411-bib-0040){ref-type="ref"}, [45](#jcsm12411-bib-0045){ref-type="ref"}, [46](#jcsm12411-bib-0046){ref-type="ref"}, [47](#jcsm12411-bib-0047){ref-type="ref"}, [53](#jcsm12411-bib-0053){ref-type="ref"}, [74](#jcsm12411-bib-0074){ref-type="ref"} and 1 study was a randomized controlled trial examining the effect of nutritional supplementation on bone mineral density and risk of falls.[24](#jcsm12411-bib-0024){ref-type="ref"} Most of the studies were performed in Europe (12 studies),[26](#jcsm12411-bib-0026){ref-type="ref"}, [27](#jcsm12411-bib-0027){ref-type="ref"}, [33](#jcsm12411-bib-0033){ref-type="ref"}, [35](#jcsm12411-bib-0035){ref-type="ref"}, [40](#jcsm12411-bib-0040){ref-type="ref"}, [42](#jcsm12411-bib-0042){ref-type="ref"}, [47](#jcsm12411-bib-0047){ref-type="ref"}, [49](#jcsm12411-bib-0049){ref-type="ref"}, [55](#jcsm12411-bib-0055){ref-type="ref"}, [73](#jcsm12411-bib-0073){ref-type="ref"}, [74](#jcsm12411-bib-0074){ref-type="ref"} and Asia (12 studies),[18](#jcsm12411-bib-0018){ref-type="ref"}, [29](#jcsm12411-bib-0029){ref-type="ref"}, [30](#jcsm12411-bib-0030){ref-type="ref"}, [31](#jcsm12411-bib-0031){ref-type="ref"}, [44](#jcsm12411-bib-0044){ref-type="ref"}, [48](#jcsm12411-bib-0048){ref-type="ref"}, [50](#jcsm12411-bib-0050){ref-type="ref"}, [51](#jcsm12411-bib-0051){ref-type="ref"}, [53](#jcsm12411-bib-0053){ref-type="ref"}, [54](#jcsm12411-bib-0054){ref-type="ref"}, [72](#jcsm12411-bib-0072){ref-type="ref"}, [75](#jcsm12411-bib-0075){ref-type="ref"} followed by Australia (5 studies),[28](#jcsm12411-bib-0028){ref-type="ref"}, [37](#jcsm12411-bib-0037){ref-type="ref"}, [38](#jcsm12411-bib-0038){ref-type="ref"}, [39](#jcsm12411-bib-0039){ref-type="ref"}, [46](#jcsm12411-bib-0046){ref-type="ref"} South America (4 studies),[32](#jcsm12411-bib-0032){ref-type="ref"}, [36](#jcsm12411-bib-0036){ref-type="ref"}, [41](#jcsm12411-bib-0041){ref-type="ref"}, [43](#jcsm12411-bib-0043){ref-type="ref"} and North America (3 studies).[24](#jcsm12411-bib-0024){ref-type="ref"}, [25](#jcsm12411-bib-0025){ref-type="ref"}, [34](#jcsm12411-bib-0034){ref-type="ref"} The prevalence of falls ranged from 4.2% to 63.8%, and the prevalence of fractures ranged from 3.5% to 63.6% in the studies. Follow‐up periods varied from 1 to 3 years for falls and 2 to 11 years for fractures.

###### 

Study characteristics and falls and fractures outcomes

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author             Year   *N*                                           Mean age ± *SD* (years)   Female, *n* (%)   Population                 Continent       Falls         Fractures                       
  ------------------ ------ --------------------------------------------- ------------------------- ----------------- -------------------------- --------------- ------------- ----------------- ------------- ------------------
  Bae                2017   3901                                          ≥65                       2259 (57.9)       Community                  Asia            109 (2.5)     Cross‐sectional   NA            NA

  Benjumea           2018   534                                           74.4 ± 8.2                403 (75.5)        Outpatient                 South America   309 (60.4)    Cross‐sectional   NA            NA

  Bischoff‐Ferrari   2015   445                                           71.0 ± 4.61               246 (55.3)        Community                  North America   231 (51.9)    RCT               NA            NA

  Buckinx            2018   565                                           82.8 ± 9.0                413 (73.1)        Nursing home               Europe          211 (37.3)    Prospective       NA            NA

  Cawthon            2015   5934                                          73.6 ± 6.0                0                 Community                  North America   NA            NA                207 (3.5)     Prospective

  Chalhoub           2015   6658                                          74.34 ± 5.0               1114 (16.7)       Community                  North America   1518 (22.8)   Retrospective     1142 (17.2)   Prospective

  Clynes             2015   298                                           76.1 ± 2.57               142 (47.7)        Community                  Europe          190 (63.8)    Cross‐sectional   70 (23.5)     Cross‐sectional

  Dietzel            2015   288                                           71.9 ± 7.5                142 (49.3)        Community                  Europe          47 (16.0)     Cross‐sectional   NA            NA

  Gadelha            2018   196                                           68.6 ± 6.45               196 (100)         Community                  South America   65 (33.2)     Cross‐sectional   NA            NA

  Hars               2016   913                                           65.0 ± 1.4                729 (79.9)        Community                  Europe          NA            NA                40 (4.4)      Prospective

  Henwood            2017   58                                            84.5 ± 8.2                41 (70.7)         Nursing home               Australia       24 (41.4)     Prospective       NA            NA

  Hida               2013   2868                                          71.3 ± 10.4               2197 (76.6)       Hospital and outpatients   Asia            NA            NA                357 (12.4)    Cross‐sectional

  Hida               2016   1824                                          70.4 ± 9.5                1824 (100)        Hospital and outpatients   Asia            NA            NA                216 (11.8)    Retrospective

  Hong               2015   3077                                          78.0 ± 6.6                1492 (48.5)       Hospital and community     Asia            NA            NA                757 (24.6)    Cross‐sectional

  Huo                2015   680                                           79.0 ± 7.1                455 (66.9)        Outpatient                 Australia       NA            NA                242 (35.6)    Cross‐sectional

  Huo                2016   680                                           79.0 ± 9.0                418 (61.5)        Outpatient                 Australia       NA            NA                293 (43.1)    Cross‐sectional

  Iolascon           2015   121                                           67.2 ± 8.47               121 (100)         Outpatient                 Europe          NA            NA                77 (63.6)     Retrospective

  Landi              2012   260                                           86.7 ± 5.4                177 (68.1)        Community                  Europe          37 (14.2)     Prospective       NA            NA

  Lera               2017   1006                                          67.6 ± 5.9                687 (68.3)        Community                  South America   332 (33.0)    Cross‐sectional   NA            NA

  Locquet            2018   288                                           74.7 ± 5.7                170 (59.0)        Community                  Europe          NA            NA                134 (46.5)    Cross‐sectional

  Martinez           2015   110                                           71.0 ± 8.2                46 (41.8)         Hospital                   South America   28 (25.5)     Cross‐sectional   NA            NA

  Matsumoto          2017   162                                           74.2 ± 7.1                103 (63.6)        Community                  Asia            50 (30.9)     Prospective       NA            NA

  Menant             2017   419                                           81.2 ± 4.5                207 (49.4)        Community                  Australia       194 (46.3)    Prospective       NA            NA

  Meng               2015   771                                           73.0 ± 5.7                359 (46.6)        Community                  Asia            173 (22.4)    Cross‐sectional   NA            NA

  Schaap             2018   496                                           75.2 ± 6.4                250 (50.4)        Community                  Europe          130 (26.6)    Prospective       60 (12.1)     Prospective

  Scott              2017   861                                           76.6 ± 5.5                0                 Community                  Australia       371 (30.0)    Prospective       152 (17.7)    Prospective

  Sjöblom            2013   590                                           67.9 ± 1.9                590 (100)         Community                  Europe          119 (21.7)    Cross‐sectional   85 (14.9)     Cross‐sectional

  Steihaug           2018   201[b](#jcsm12411-note-0004){ref-type="fn"}   79.4 ± 8.2                151 (75.1)        Hospital                   Europe          NA            NA                14 (7.0)\     Cross‐sectional\
                                                                                                                                                                                                 15 (7.9)      Prospective

  Tanimoto           2014   1110                                          73.4 ± 6.0                738 (66.5)        Community                  Asia            220 (19.8)    Cross‐sectional   NA            NA

  Trajanoska         2018   5911                                          69.2 ± 9.1                3361 (56.8)       Community                  Europe          1097 (18.6)   Cross‐sectional   939 (15.9)    Cross‐sectional

  Van Puyenbroeck    2012   276                                           83.4                      193 (69.9)        Nursing home               Europe          69 (25.0)     Prospective       NA            NA

  Woo                2014   2848                                          73.17 (SE 0.14)           1675 (58.8)       Community                  Asia            120 (4.2)     Cross‐sectional   NA            NA

  Yamada             2013   1882                                          74.9 ± 5.5                1314 (69.8)       Community                  Asia            470 (25.0)    Cross‐sectional   NA            NA

  Yoo                2016   1970                                          66.3 ± 9.1                1221 (62)         Hospital and community     Asia            NA            NA                359 (18.2)    Case--control

  Yoshimura          2018   637                                           74 ± 13                   366 (57.5)        Hospital                   Asia            NA            NA                131 (20.6)    Cross‐sectional

  Yu                 2014   4000                                          72.5 ± 5.2                2000 (50)         Community                  Asia            NA            NA                565 (14.1)    Prospective
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*N*, sample size; NA, not applicable; RCT, randomised controlled trial; SD, standard deviation.

Prevalence is reported for cross‐sectional study design; incidence is reported for prospective study design.

*n* = 191 for complete follow‐up.

*Table* [2](#jcsm12411-tbl-0002){ref-type="table"} shows the prevalence and applied diagnostic criteria of sarcopenia. The prevalence of sarcopenia varied from 0.3% to 73.0%, depending on the sarcopenia definition applied and the study population. Sarcopenia was diagnosed using one definition[18](#jcsm12411-bib-0018){ref-type="ref"}, [26](#jcsm12411-bib-0026){ref-type="ref"}, [29](#jcsm12411-bib-0029){ref-type="ref"}, [30](#jcsm12411-bib-0030){ref-type="ref"}, [31](#jcsm12411-bib-0031){ref-type="ref"}, [32](#jcsm12411-bib-0032){ref-type="ref"}, [33](#jcsm12411-bib-0033){ref-type="ref"}, [34](#jcsm12411-bib-0034){ref-type="ref"}, [36](#jcsm12411-bib-0036){ref-type="ref"}, [37](#jcsm12411-bib-0037){ref-type="ref"}, [38](#jcsm12411-bib-0038){ref-type="ref"}, [39](#jcsm12411-bib-0039){ref-type="ref"}, [40](#jcsm12411-bib-0040){ref-type="ref"}, [41](#jcsm12411-bib-0041){ref-type="ref"}, [42](#jcsm12411-bib-0042){ref-type="ref"}, [43](#jcsm12411-bib-0043){ref-type="ref"}, [47](#jcsm12411-bib-0047){ref-type="ref"}, [48](#jcsm12411-bib-0048){ref-type="ref"}, [49](#jcsm12411-bib-0049){ref-type="ref"}, [50](#jcsm12411-bib-0050){ref-type="ref"}, [53](#jcsm12411-bib-0053){ref-type="ref"}, [54](#jcsm12411-bib-0054){ref-type="ref"}, [72](#jcsm12411-bib-0072){ref-type="ref"}, [73](#jcsm12411-bib-0073){ref-type="ref"}, [75](#jcsm12411-bib-0075){ref-type="ref"} or more than one definition.[24](#jcsm12411-bib-0024){ref-type="ref"}, [25](#jcsm12411-bib-0025){ref-type="ref"}, [27](#jcsm12411-bib-0027){ref-type="ref"}, [28](#jcsm12411-bib-0028){ref-type="ref"}, [35](#jcsm12411-bib-0035){ref-type="ref"}, [44](#jcsm12411-bib-0044){ref-type="ref"}, [45](#jcsm12411-bib-0045){ref-type="ref"}, [46](#jcsm12411-bib-0046){ref-type="ref"}, [51](#jcsm12411-bib-0051){ref-type="ref"}, [55](#jcsm12411-bib-0055){ref-type="ref"}, [74](#jcsm12411-bib-0074){ref-type="ref"} Out of the 36 included studies, EWGSOP (23 studies) was the most commonly used definition,[24](#jcsm12411-bib-0024){ref-type="ref"}, [25](#jcsm12411-bib-0025){ref-type="ref"}, [28](#jcsm12411-bib-0028){ref-type="ref"}, [32](#jcsm12411-bib-0032){ref-type="ref"}, [33](#jcsm12411-bib-0033){ref-type="ref"}, [34](#jcsm12411-bib-0034){ref-type="ref"}, [35](#jcsm12411-bib-0035){ref-type="ref"}, [36](#jcsm12411-bib-0036){ref-type="ref"}, [37](#jcsm12411-bib-0037){ref-type="ref"}, [38](#jcsm12411-bib-0038){ref-type="ref"}, [39](#jcsm12411-bib-0039){ref-type="ref"}, [40](#jcsm12411-bib-0040){ref-type="ref"}, [41](#jcsm12411-bib-0041){ref-type="ref"}, [42](#jcsm12411-bib-0042){ref-type="ref"}, [43](#jcsm12411-bib-0043){ref-type="ref"}, [44](#jcsm12411-bib-0044){ref-type="ref"}, [45](#jcsm12411-bib-0045){ref-type="ref"}, [46](#jcsm12411-bib-0046){ref-type="ref"}, [47](#jcsm12411-bib-0047){ref-type="ref"}, [48](#jcsm12411-bib-0048){ref-type="ref"}, [49](#jcsm12411-bib-0049){ref-type="ref"}, [51](#jcsm12411-bib-0051){ref-type="ref"} followed by FNIH (7 studies),[24](#jcsm12411-bib-0024){ref-type="ref"}, [25](#jcsm12411-bib-0025){ref-type="ref"}, [27](#jcsm12411-bib-0027){ref-type="ref"}, [35](#jcsm12411-bib-0035){ref-type="ref"}, [45](#jcsm12411-bib-0045){ref-type="ref"}, [55](#jcsm12411-bib-0055){ref-type="ref"}, [56](#jcsm12411-bib-0056){ref-type="ref"} Baumgartner definition (5 studies),[24](#jcsm12411-bib-0024){ref-type="ref"}, [25](#jcsm12411-bib-0025){ref-type="ref"}, [26](#jcsm12411-bib-0026){ref-type="ref"}, [27](#jcsm12411-bib-0027){ref-type="ref"}, [28](#jcsm12411-bib-0028){ref-type="ref"} AWGS (4 studies),[18](#jcsm12411-bib-0018){ref-type="ref"}, [51](#jcsm12411-bib-0051){ref-type="ref"}, [53](#jcsm12411-bib-0053){ref-type="ref"}, [54](#jcsm12411-bib-0054){ref-type="ref"} and IWGS (4 studies).[24](#jcsm12411-bib-0024){ref-type="ref"}, [25](#jcsm12411-bib-0025){ref-type="ref"}, [27](#jcsm12411-bib-0027){ref-type="ref"}, [35](#jcsm12411-bib-0035){ref-type="ref"}

###### 

Prevalence and diagnostic criteria of sarcopenia of the included studies

  Author             Year   *N*    Sarcopenia          Diagnostic criteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  ------------------ ------ ------ ------------------- --------------------- ----------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ -------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------
  Bae                2017   3827   Cho et al.          1619 (42.3)           DXA                                                                           ASM (as % body weight): M: \<30.3%; F: \<23.8%                                                                           NA                         NA                                                                                                                                                                                  NA                                               NA
  Benjumea           2018   534    EWGSOP              380 (71.2)            Lee equation                                                                  ASM/ht^2^: M: ≤6.37 kg/m^2^; F: ≤8.90 kg/m^2^                                                                            HGS                        M: \<30 kg; F: \<20 kg                                                                                                                                                              4‐m GS                                           ≤0.8 m/s
  Bischoff‐Ferrari   2015   443    Baumgartner         49 (11.0)             DXA                                                                           ALM/ht^2^: M: ≤7.26 kg/m^2^; F: ≤5.45 kg/m^2^                                                                            NA                         NA                                                                                                                                                                                  NA                                               NA
                            443    Delmonico 1         75 (16.9)             DXA                                                                           ALM/ht^2^: M: ≤7.25 kg/m^2^; F: ≤5.67 kg/m^2^                                                                            NA                         NA                                                                                                                                                                                  NA                                               NA
                            443    Delmonico 2         95 (21.4)             DXA                                                                           Observed ALM---predicted ALM: \<20th percentile of the sex‐specific distribution                                         NA                         NA                                                                                                                                                                                  NA                                               NA
                            445    EWGSOP              31 (7.0)              DXA                                                                           ALM/ht^2^: M: ≤7.26 kg/m^2^; F: ≤5.54 kg/m^2^                                                                            HGS                        M: \<30 kg; F: \<20 kg                                                                                                                                                              15‐ft GS                                         \<0.8 m/s
                            440    IWGS                22 (4.9)              DXA                                                                           ALM/ht^2^: M: ≤7.23 kg/m^2^; F: ≤5.67 kg/m^2^                                                                            NA                         NA                                                                                                                                                                                  15‐ft GS                                         \<1.0 m/s
                            445    SCWD                12 (2.7)              DXA                                                                           ALM/ht^2^: M: ≤6.81 kg/m^2^; F: ≤5.18 kg/m^2^                                                                            NA                         NA                                                                                                                                                                                  15‐ft GS                                         \<1.0 m/s
                            445    Muscaritoli         104 (23.6)            DXA                                                                           SM/body mass: M: ≤37%; F: ≤28%                                                                                           NA                         NA                                                                                                                                                                                  15‐ft GS                                         \<0.8 m/s
                            443    FNIH 1              52 (11.7)             DXA                                                                           ALM~BMI~: M: \<0.789; F: \<0.512                                                                                         NA                         NA                                                                                                                                                                                  NA                                               NA
                            445    FNIH 2              14 (3.1)              DXA                                                                           ALM~BMI~: M: \<0.789; F: \<0.512                                                                                         HGS                        M: \<26 kg; F: \<16 kg                                                                                                                                                              NA                                               NA
  Buckinx            2018   247    EWGSOP              166 (67.2)            BIA                                                                           Not specified                                                                                                            HGS                        Not specified                                                                                                                                                                       SPPB                                             ≤8 points
  Cawthon            2015   5934   Baumgartner         1301 (21.9)           DXA                                                                           ALM/ht^2^: M: ≤7.23 kg/m^2^                                                                                              NA                         NA                                                                                                                                                                                  NA                                               NA
                            5934   EWGSOP              257 (4.3)             DXA                                                                           ALM/ht^2^: M: ≤7.23 kg/m^2^                                                                                              HGS                        M: \<30 kg                                                                                                                                                                          6‐m GS                                           ≤0.8 m/s
                            5934   IWGS                277 (4.7)             DXA                                                                           ALM/ht^2^: M: ≤7.23 kg/m^2^                                                                                              NA                         NA                                                                                                                                                                                  6‐m GS                                           \<1.0 m/s
                            5934   FNIH 1              88 (1.5)              DXA                                                                           ALM~BMI~: M: \<0.789                                                                                                     NA                         NA                                                                                                                                                                                  6‐m GS                                           ≤0.8 m/s
                            5934   FNIH 2              18 (0.3)              DXA                                                                           ALM~BMI~: M: \<0.789                                                                                                     HGS                        M: \<26 kg                                                                                                                                                                          6‐m GS                                           ≤0.8 m/s
                            5934   Newman              1186 (20.0)           DXA                                                                           Residual of actual ALM minus predicted ALM: ≤−0.204 kg/m^2^                                                              NA                         NA                                                                                                                                                                                  NA                                               NA
  Chalhoub           2015   6658   EWGSOP              371 (5.6)             DXA                                                                           ALM adjusted for height and fat mass: 20th percentile of the distribution of residuals                                   HGS                        M: \<30 kg; F: \<20 kg                                                                                                                                                              6‐m GS                                           \<0.8 m/s
  Clynes             2015   298    IWGS                25 (8.4)              DXA                                                                           ALM/ht^2^: M: ≤7.23 kg/m^2^; F: ≤5.67 kg/m^2^                                                                            NA                         NA                                                                                                                                                                                  3‐m GS                                           \<1.0 m/s
                            298    EWGSOP              10 (3.4)              DXA                                                                           SMI: M: ≤7.26 kg/m^2^; F: ≤5.5 kg/m^2^                                                                                   HGS                        M: \<30 kg; F: \<20 kg                                                                                                                                                              3‐m GS                                           ≤0.8 m/s
                            298    FNIH                6 (2.0)               DXA                                                                           ALM~BMI~: M: \<0.789; F: \<0.512                                                                                         HGS                        M: \<26 kg; F: \<16 kg                                                                                                                                                              NA                                               NA
  Dietzel            2015   288    Baumgartner         34 (11.8)             DXA                                                                           ASM/ht^2^: M: \<7.26 kg/m^2^; F: \<5.5 kg/m^2^                                                                           NA                         NA                                                                                                                                                                                  NA                                               NA
  Gadelha            2018   196    EWGSOP              36 (18.4)             DXA                                                                           SMM (as % body mass): not specified                                                                                      Isokinetic muscle torque   Not specified                                                                                                                                                                       TUG                                              Not specified
  Hars               2016   913    Baumgartner         102 (11.2)            DXA                                                                           ALM/ht^2^: M: \<7.26 kg/m^2^; F: \<5.45 kg/m^2^                                                                          NA                         NA                                                                                                                                                                                  NA                                               NA
                            913    Delmonico 1         157 (17.2)            DXA                                                                           ALM/ht^2^: M: \<7.25 kg/m^2^; F: \<5.67 kg/m^2^                                                                          NA                         NA                                                                                                                                                                                  NA                                               NA
                            913    Delmonico 2         184 (20.2)            DXA                                                                           Observed ALM minus predicted ALM: \<20th percentile of the sex‐specific distribution                                     NA                         NA                                                                                                                                                                                  NA                                               NA
                            913    IWGS                156 (17.1)            DXA                                                                           ALM/ht^2^: M: ≤7.23 kg/m^2^; F: ≤5.67 kg/m^2^                                                                            NA                         NA                                                                                                                                                                                  NA                                               NA
                            913    SCWD                42 (4.6)              DXA                                                                           ALM/ht^2^: M: ≤6.81 kg/m^2^; F: ≤5.18 kg/m^2^                                                                            NA                         NA                                                                                                                                                                                  NA                                               NA
                            913    FNIH                32 (3.5)              DXA                                                                           ALM~BMI~: M: \<0.789; F: \<0.512                                                                                         NA                         NA                                                                                                                                                                                  NA                                               NA
  Henwood            2017   58     EWGSOP              23 (40.2)             BIA                                                                           SMM/ht^2^: M: \<8.87 kg/m^2^; F: \<6.42 kg/m^2^                                                                          HGS                        M: \<30 kg; F: \<20 kg                                                                                                                                                              2.4‐m GS                                         \<0.8 m/s
  Hida               2013   2868   Sanada              1019 (35.5)           DXA                                                                           ALM/ht^2^: M: \<6.87 kg/m^2^; F: \<5.46 kg/m^2^                                                                          NA                         NA                                                                                                                                                                                  NA                                               NA
  Hida               2016   1824   Sanada              493 (27.0)            DXA                                                                           ALM/ht^2^: F: \<5.46 kg/m^2^                                                                                             NA                         NA                                                                                                                                                                                  NA                                               NA
  Hong               2015   3077   Cheng               966 (31.4)            DXA                                                                           SMI: M: \<7.01 kg/m^2^; F: \<5.42 kg/m^2^                                                                                NA                         NA                                                                                                                                                                                  NA                                               NA
  Huo                2015   680    EWGSOP              345 (50.7)            DXA                                                                           ALM/ht^2^: M: \<7.26 kg/m^2^; F: \<5.5 kg/m^2^                                                                           HGS                        M: \<30 kg; F: \<20 kg                                                                                                                                                              GS                                               \<0.8 m/s
  Huo                2016   680    EWGSOP              380 (55.9)            DXA                                                                           ALM/ht^2^: M: \<7.26 kg/m^2^; F: \<5.5 kg/m^2^                                                                           HGS                        M: \<30 kg; F: \<20 kg                                                                                                                                                              GS                                               \<0.8 m/s
  Iolascon           2015   121    FNIH 1              10 (8.3)              DXA                                                                           ALM~BMI~: F: \<0.512                                                                                                     HGS                        F: ≥16                                                                                                                                                                              4‐m GS                                           ≤0.8 m/s
                                   FNIH 2              13 (10.7)             DXA                                                                           ALM~BMI~: F: \<0.512                                                                                                     HGS                        F: \<16                                                                                                                                                                             4‐m GS                                           ≤0.8 m/s
  Landi              2012   260    EWGSOP              66 (25.4)             MAMC                                                                          M: \<21.1 cm; F: \<19.2 cm                                                                                               HGS                        M: \<30 kg; F: \<20 kg                                                                                                                                                              4‐m GS                                           \<0.8 m/s
  Lera               2017   1006   EWGSOP              192 (19.1)            DXA                                                                           ASM/ht^2^: M: \<7.19 kg/m^2^; F: \<5.77 kg/m^2^                                                                          HGS                        M: ≤27 kg; F: ≤15 kg                                                                                                                                                                3‐m GS                                           \<0.8 m/s
  Locquet            2018   288    EWGSOP              43 (14.9)             DXA                                                                           AMM/ht^2^: M: \<7.26 kg/m^2^; F: \<5.50 kg/m^2^                                                                          HGS                        M: \<30 kg; F: \<20 kg                                                                                                                                                              SPPB                                             \<8 points
  Martinez           2015   110    EWGSOP              24 (21.8)             Lee equation                                                                  SMM/ht^2^: M: ≤8.90 kg/m^2^; F: ≤6.37 kg/m^2^                                                                            HGS                        M: \<30 kg; F: \<20 kg                                                                                                                                                              6‐m GS                                           ≤0.8 m/s
  Matsumoto          2017   162    AWGS                9 (5.6)               BIA                                                                           M: \<7.0 kg/m^2^; F: \<5.7 kg/m^2^                                                                                       HGS                        M: \<26 kg; F: \<18 kg                                                                                                                                                              5‐m GS                                           ≤0.8 m/s
  Menant             2017   410    EWGSOP              88 (21.5)             DXA                                                                           ASM/ht^2^: M: \<7.2 kg/m^2^; F: \<5.5 kg/m^2^                                                                            HGS                        M: \<30 kg; F: \<20 kg                                                                                                                                                              6‐m GS                                           ≤0.8 m/s
                            419    Baumgartner         97 (23.2)             DXA                                                                           ASM/ht^2^: M: \<7.26 kg/m^2^; F: \<5.45 kg/m^2^                                                                          NA                         NA                                                                                                                                                                                  NA                                               NA
                            419    Scott               139 (33.2)            DXA                                                                           Bottom tertile of the residuals from the regression of ALM (g) on height (m) and fat mass (g): M: \<326.4; F: \<2217.8   NA                         NA                                                                                                                                                                                  NA                                               NA
                            419    Levine & Crimmins   57 (13.6)             DXA                                                                           ALM (as % body mass): M: \<25.72%; F: \<19.43%                                                                           NA                         NA                                                                                                                                                                                  NA                                               NA
  Menant             2017   419    Bouchard            306 (73.0)            DXA                                                                           ASM/ht^2^: M: \<8.51 kg/m^2^; F: \<6.29 kg/m^2^                                                                          NA                         NA                                                                                                                                                                                  NA                                               NA
                            314    HGS‐based           127 (40.4)            NA                                                                            NA                                                                                                                       HGS                        M: \<30 kg; F: \<20 kg                                                                                                                                                              NA                                               NA
                            419    KES‐based           84 (20.0)             NA                                                                            NA                                                                                                                       KES                        M: \<23.64 kg; F: \<15.24 kg                                                                                                                                                        NA                                               NA
  Meng               2015   771    EWGSOP 1            44 (5.7)              DXA                                                                           ALM/ht^2^: M: \<6.39 kg/m^2^; F: \<4.84 kg/m^2^                                                                          HGS                        M: \<30 kg; F: \<20 kg                                                                                                                                                              5‐m GS                                           \<0.8 m/s
                                   EWGSOP 2            75 (9.7)              DXA                                                                           ALM (as % body mass): M: \<27.1%; F: \<22.3%                                                                             HGS                        M: \<30 kg; F: \<20 kg                                                                                                                                                              5‐m GS                                           \<0.8 m/s
  Schaap             2018   496    EWGSOP              158 (31.9)            DXA                                                                           ASM/ht^2^: M: ≤7.26 kg/m^2^; F: ≤ 5.45 kg/m^2^                                                                           HGS                        M: \<30 kg; F: \<20 kg                                                                                                                                                              GS (walk 3 m, a turn of 180° and walk the 3 m)   ≤0.8 m/s
                                   FNIH 1              39 (7.9)              DEXA                                                                          M: \<19.75 kg; F: \<15.02 kg                                                                                             HGS                        M: \<26 kg; F: \<16 kg                                                                                                                                                              NA                                               NA
                                   FNIH 2              31 (6.3)              DEXA                                                                          M: \<19.75 kg; F: \<15.02 kg                                                                                             HGS                        M: \<26 kg; F: \<16 kg                                                                                                                                                              GS (walk 3 m, a turn of 180° and walk the 3 m)   ≤0.8 m/s
  Scott              2017   1486   EWGSOP              237 (15.9)            DXA                                                                           ALM/ht^2^: M: \<7.25 kg/m^2^                                                                                             HGS                        M: \<30 kg                                                                                                                                                                          6‐m GS                                           ≤0.8 m/s
                            1486   FNIH                119 (8.0)             DXA                                                                           ALM~BMI~: M: \<0.789                                                                                                     HGS                        M: \<26 kg                                                                                                                                                                          NA                                               NA
  Steihaug           2018   201    EWGSOP              77 (38.3)             Heymsfield formula using anthropometry to estimate ALM (Kim et al. formula)   ALM/ht^2^: M: ≤7.25 kg/m^2^; F: ≤5.67 kg/m^2^                                                                            HGS                        M: ≤30 kg; F: ≤20 kg                                                                                                                                                                Questionnaire (new mobility score)               \<5 points
  Sjöblom            2013   590    NG                  69 (11.7)             DXA                                                                           Relative SMI: F: \<6.3 kg/m^2^                                                                                           HGS                        F: \<22.3 kPA                                                                                                                                                                       10‐m GS                                          F: \>7 s
  Tanimoto           2014   1110   EWGSOP              160 (14.4)            BIA                                                                           AMM/ht^2^: M: \<7.0 kg/m^2^; F: \<5.8 kg/m^2^                                                                            HGS                        Lowest HGS quartile                                                                                                                                                                 5‐m GS                                           Slowest GS quartile
  Trajanoska         2018   5911   EWGSOP              260 (4.4)             DXA                                                                           ALM/ht^2^: M: ≤7.25 kg/m^2^; F: ≤5.67 kg/m^2^                                                                            HGS                        M: ≤29 kg (if BMI ≤ 24); ≤30 kg (if BMI ≤ 24.1--28); ≤32 kg (if BMI \> 28); F: ≤17 kg (if BMI ≤ 23); ≤17.3 kg (if BMI ≤ 23.1--26), ≤18 kg (BMI ≤ 26.1--29), ≤21 kg (if BMI \> 29)   5.79‐m GS                                        M: \<0.65 m/s (if height ≤ 173 cm) or \<0.76 m/s (if height \> 173 cm); F: \<0.65 m/s (if height ≤ 159 cm) or \<0.76 m/s (if height \> 159 cm)
  Van Puyenbroeck    2012   276    NG                  67 (24.3)             BIA                                                                           SM/ht^2^: M: 8.058 kg/m^2^; F: 6.154 kg/m^2^                                                                             NA                         NA                                                                                                                                                                                  NA                                               NA
                            276    NG                  225 (81.5)            BIA                                                                           SM/weight × 100: M: \<33.94; F: \<24.76                                                                                  NA                         NA                                                                                                                                                                                  NA                                               NA
                            276    NG                  178 (64.5)            BIA                                                                           SM: M: \<25.99 kg; F: \<16.15 kg                                                                                         NA                         NA                                                                                                                                                                                  NA                                               NA
  Woo                2014   2848   Kim                 1404 (49.3)           DXA                                                                           ASM/weight: M: \<29.9%; F: \<25.1%                                                                                       NA                         NA                                                                                                                                                                                  NA                                               NA
  Yamada             2013   1882   EWGSOP              414 (22.0)            BIA                                                                           Appendicular SMM/ht^2^: M: \<6.75 kg/m^2^; F: \<5.07 kg/m^2^                                                             HGS                        M: \<30 kg; F: \<20 kg                                                                                                                                                              10‐m GS                                          \<0.8 m/s
  Yoo                2016   1970   AWGS                352 (17.8)            DXA                                                                           SMM/ht^2^: M: \<7.0 kg/m^2^; F: \<5.4 kg/m^2^                                                                            NA                         NA                                                                                                                                                                                  NA                                               NA
                            1970   EWGSOP              439 (22.3)            DXA                                                                           SMM/ht^2^: M: \<7.26 kg/m^2^; F: \<5.5 kg/m^2^                                                                           NA                         NA                                                                                                                                                                                  NA                                               NA
  Yoshimura          2018   637    AWGS                343 (53.0)            BIA                                                                           SM/ht^2^: M: \<7.0 kg/m^2^; F: \<5.7 kg/m^2^                                                                             HGS                        M: \<26 kg; F: \<18 kg                                                                                                                                                              NA                                               NA
  Yu                 2014   4000   AWGS                293 (7.3)             DXA                                                                           ASM/ht^2^: M: \<7.0 kg/m^2^; F: \<5.4 kg/m^2^                                                                            HGS                        M: \<26 kg; F: \<18 kg                                                                                                                                                              6‐m GS                                           \<0.8 m/s

ALM, appendicular lean mass; AMM, appendicular muscle mass; ASM, appendicular skeletal muscle mass; AWGS, Asia Working Group for Sarcopenia; BIA, bioelectrical impedance analysis; BMI, body mass index; DXA, dual energy X‐ray absorptiometry; EWGSOP, European Working Group on Sarcopenia in Older People; F, females; FNIH, Foundation for the National Institutes of Health; GS, gait speed; HGS, handgrip strength; ht, height; IWGS, International Working Group on Sarcopenia; KES, knee extension strength; M, males; MAMC, mid‐arm muscle circumference; *N*, sample size; NA, not applicable; NG, not given; SCWD, Society for Sarcopenia, Cachexia, and Wasting Disorders; SM, skeletal muscle; SMM, skeletal muscle mass; SMI, skeletal muscle index; SPPB, short physical performance battery; TUG, Timed Up & Go.

Study quality {#jcsm12411-sec-0010}
-------------

[Online Resource S4](#jcsm12411-supitem-0004){ref-type="supplementary-material"} shows the results of the NOS quality assessment of the included studies. The quality of 12 falls studies[24](#jcsm12411-bib-0024){ref-type="ref"}, [26](#jcsm12411-bib-0026){ref-type="ref"}, [33](#jcsm12411-bib-0033){ref-type="ref"}, [35](#jcsm12411-bib-0035){ref-type="ref"}, [37](#jcsm12411-bib-0037){ref-type="ref"}, [41](#jcsm12411-bib-0041){ref-type="ref"}, [45](#jcsm12411-bib-0045){ref-type="ref"}, [48](#jcsm12411-bib-0048){ref-type="ref"}, [53](#jcsm12411-bib-0053){ref-type="ref"}, [72](#jcsm12411-bib-0072){ref-type="ref"}, [73](#jcsm12411-bib-0073){ref-type="ref"}, [75](#jcsm12411-bib-0075){ref-type="ref"} and 14 fracture studies[18](#jcsm12411-bib-0018){ref-type="ref"}, [25](#jcsm12411-bib-0025){ref-type="ref"}, [27](#jcsm12411-bib-0027){ref-type="ref"}, [29](#jcsm12411-bib-0029){ref-type="ref"}, [30](#jcsm12411-bib-0030){ref-type="ref"}, [31](#jcsm12411-bib-0031){ref-type="ref"}, [34](#jcsm12411-bib-0034){ref-type="ref"}, [35](#jcsm12411-bib-0035){ref-type="ref"}, [45](#jcsm12411-bib-0045){ref-type="ref"}, [49](#jcsm12411-bib-0049){ref-type="ref"}, [51](#jcsm12411-bib-0051){ref-type="ref"}, [54](#jcsm12411-bib-0054){ref-type="ref"}, [55](#jcsm12411-bib-0055){ref-type="ref"}, [73](#jcsm12411-bib-0073){ref-type="ref"} was rated high. Ten studies for falls were rated as low quality.[28](#jcsm12411-bib-0028){ref-type="ref"}, [32](#jcsm12411-bib-0032){ref-type="ref"}, [34](#jcsm12411-bib-0034){ref-type="ref"}, [36](#jcsm12411-bib-0036){ref-type="ref"}, [40](#jcsm12411-bib-0040){ref-type="ref"}, [43](#jcsm12411-bib-0043){ref-type="ref"}, [44](#jcsm12411-bib-0044){ref-type="ref"}, [49](#jcsm12411-bib-0049){ref-type="ref"}, [50](#jcsm12411-bib-0050){ref-type="ref"}, [74](#jcsm12411-bib-0074){ref-type="ref"} Five studies for fractures were rated as low quality.[38](#jcsm12411-bib-0038){ref-type="ref"}, [39](#jcsm12411-bib-0039){ref-type="ref"}, [42](#jcsm12411-bib-0042){ref-type="ref"}, [46](#jcsm12411-bib-0046){ref-type="ref"}, [47](#jcsm12411-bib-0047){ref-type="ref"}

Association of sarcopenia with falls {#jcsm12411-sec-0011}
------------------------------------

Twenty‐two studies investigated the association of sarcopenia and falls, of which 10 studies (45%) reported higher risks of falls among sarcopenic individuals compared with non‐sarcopenic individuals.[28](#jcsm12411-bib-0028){ref-type="ref"}, [34](#jcsm12411-bib-0034){ref-type="ref"}, [40](#jcsm12411-bib-0040){ref-type="ref"}, [41](#jcsm12411-bib-0041){ref-type="ref"}, [48](#jcsm12411-bib-0048){ref-type="ref"}, [50](#jcsm12411-bib-0050){ref-type="ref"}, [53](#jcsm12411-bib-0053){ref-type="ref"}, [72](#jcsm12411-bib-0072){ref-type="ref"}, [73](#jcsm12411-bib-0073){ref-type="ref"}, [75](#jcsm12411-bib-0075){ref-type="ref"} Non‐significant associations between sarcopenia and falls were found in the remaining 12 studies.[24](#jcsm12411-bib-0024){ref-type="ref"}, [26](#jcsm12411-bib-0026){ref-type="ref"}, [32](#jcsm12411-bib-0032){ref-type="ref"}, [33](#jcsm12411-bib-0033){ref-type="ref"}, [35](#jcsm12411-bib-0035){ref-type="ref"}, [36](#jcsm12411-bib-0036){ref-type="ref"}, [37](#jcsm12411-bib-0037){ref-type="ref"}, [43](#jcsm12411-bib-0043){ref-type="ref"}, [44](#jcsm12411-bib-0044){ref-type="ref"}, [45](#jcsm12411-bib-0045){ref-type="ref"}, [49](#jcsm12411-bib-0049){ref-type="ref"}, [74](#jcsm12411-bib-0074){ref-type="ref"}

Among the 20 studies included in the meta‐analysis, a pooled OR of 1.60 for cross‐sectional studies (95% CI 1.37--1.86, *P* \< 0.001, *I* ^2^ = 34%) and a pooled OR of 1.89 for prospective studies (95% CI 1.33--2.68, *P* \< 0.001, *I* ^2^ = 37%) indicated a significantly higher risk of falls for sarcopenic compared with non‐sarcopenic individuals (*Figure* [*1*](#jcsm12411-fig-0001){ref-type="fig"}A). The results of the subgroup analyses are presented in *Figure* [*1*](#jcsm12411-fig-0001){ref-type="fig"}A--F. The significant association between sarcopenia and falls was independent of study design (*Figure* [*1*](#jcsm12411-fig-0001){ref-type="fig"}A), study population (*Figure* [*1*](#jcsm12411-fig-0001){ref-type="fig"}B), and sex (*Figure* [*1*](#jcsm12411-fig-0001){ref-type="fig"}C). When stratified by sarcopenia definition, sarcopenia diagnosed by use of EWGSOP (OR 1.62, 95% CI 1.38--1.90, *P* \< 0.001), Baumgartner (OR 1.50, 95% CI 1.07--2.12, *P* = 0.020), and IWGS (OR 2.02, 95% CI 1.09--3.74, *P* = 0.025) definitions was significantly associated with falls, but the association was insignificant for the FNIH definition (two studies) (OR 0.67, 95% CI 0.26--1.77, *P* = 0.422) (*Figure* [*1*](#jcsm12411-fig-0001){ref-type="fig"}D). The significant association between sarcopenia and falls was independent of continent (*Figure* [*1*](#jcsm12411-fig-0001){ref-type="fig"}E) and study quality (*Figure* [*1*](#jcsm12411-fig-0001){ref-type="fig"}F).

![Forest plots of odds ratio for falls in sarcopenic individuals vs. non‐sarcopenic individuals, stratified by (*A*) study design; (*B*) study population; (*C*) sex; (*D*) sarcopenia definition; (*E*) continent; and (*F*) study quality. AWGS, Asia Working Group for Sarcopenia; CI, confidence interval; EWGSOP, European Working Group on Sarcopenia in Older People; FNIH, Foundation for the National Institutes of Health; IWGS, International Working Group on Sarcopenia; OR, odds ratio.](JCSM-10-485-g001){#jcsm12411-fig-0001}

Association of sarcopenia with fractures {#jcsm12411-sec-0012}
----------------------------------------

Nineteen studies investigated the association of sarcopenia and fractures. Higher risks of fractures were reported in 11 studies (58%) among sarcopenic individuals compared with non‐sarcopenic individuals.[18](#jcsm12411-bib-0018){ref-type="ref"}, [27](#jcsm12411-bib-0027){ref-type="ref"}, [29](#jcsm12411-bib-0029){ref-type="ref"}, [30](#jcsm12411-bib-0030){ref-type="ref"}, [31](#jcsm12411-bib-0031){ref-type="ref"}, [34](#jcsm12411-bib-0034){ref-type="ref"}, [39](#jcsm12411-bib-0039){ref-type="ref"}, [46](#jcsm12411-bib-0046){ref-type="ref"}, [49](#jcsm12411-bib-0049){ref-type="ref"}, [51](#jcsm12411-bib-0051){ref-type="ref"}, [73](#jcsm12411-bib-0073){ref-type="ref"} Non‐significant associations between sarcopenia and fractures were found in eight studies.[25](#jcsm12411-bib-0025){ref-type="ref"}, [35](#jcsm12411-bib-0035){ref-type="ref"}, [38](#jcsm12411-bib-0038){ref-type="ref"}, [42](#jcsm12411-bib-0042){ref-type="ref"}, [45](#jcsm12411-bib-0045){ref-type="ref"}, [47](#jcsm12411-bib-0047){ref-type="ref"}, [54](#jcsm12411-bib-0054){ref-type="ref"}, [55](#jcsm12411-bib-0055){ref-type="ref"}

Among the 17 studies included in the meta‐analysis, a significantly higher risk of fractures was found for sarcopenic compared with non‐sarcopenic individuals (cross‐sectional studies: pooled OR 1.84, 95% CI 1.30--2.62, *P* = 0.001, *I* ^2^ = 91%; prospective studies: pooled OR 1.71, 95% CI 1.44--2.03, *P* = 0.011, *I* ^2^ = 0%) (*Figure* [*2*](#jcsm12411-fig-0002){ref-type="fig"}A). The association between sarcopenia and fractures remained significant when excluding one particular study with large CIs,[51](#jcsm12411-bib-0051){ref-type="ref"} and heterogeneity decreased from 91% to 10%. The results of the subgroup analysis are presented in *Figure* [*2*](#jcsm12411-fig-0002){ref-type="fig"}A--F. The significant association between sarcopenia and fractures was independent of study design (*Figure* [*2*](#jcsm12411-fig-0002){ref-type="fig"}A), study population (*Figure* [*2*](#jcsm12411-fig-0002){ref-type="fig"}B), and sex (*Figure* [*2*](#jcsm12411-fig-0002){ref-type="fig"}C). Sarcopenia diagnosed by use of EWGSOP (OR 1.93, 95% CI 1.19--3.13, *P* = 0.008) and Sanada *et al*. (OR 1.66, 95% CI 1.26--2.18, *P* \< 0.001) definitions was associated with fractures, while the association between sarcopenia and fractures was not significant for sarcopenia diagnosed with AWGS (3 studies), FNIH (3 studies), and IWGS (2 studies) definitions (*Figure* [*2*](#jcsm12411-fig-0002){ref-type="fig"}D). The significant association between sarcopenia and fractures was independent of continent (*Figure* [*2*](#jcsm12411-fig-0002){ref-type="fig"}E) and study quality (*Figure* [*2*](#jcsm12411-fig-0002){ref-type="fig"}F).

![Forest plots of odds ratio for fractures in sarcopenic individuals vs. non‐sarcopenic individuals, stratified by (*A*) study design; (*B*) study population; (*C*) sex; (*D*) sarcopenia definition; (*E*) continent; and (*F*) study quality. AWGS, Asia Working Group for Sarcopenia; CI, confidence interval; EWGSOP, European Working Group on Sarcopenia in Older People; FNIH, Foundation for the National Institutes of Health; IWGS, International Working Group on Sarcopenia; OR, odds ratio.](JCSM-10-485-g002){#jcsm12411-fig-0002}

Publication bias {#jcsm12411-sec-0013}
----------------

Asymmetry was observed by visual inspection of funnel plots ([Online Resource S5](#jcsm12411-supitem-0005){ref-type="supplementary-material"}). However, Egger\'s regression test (*P* = 0.463 for falls and *P* = 0.928 for fractures) and Begg\'s test (*P* = 0.627 for falls and *P* = 0.232 for fractures) indicated no statistically significant publication bias among the studies in this meta‐analysis.

Discussion {#jcsm12411-sec-0014}
==========

This systematic review and meta‐analysis highlights the positive association between sarcopenia, falls, and fractures; this was independent of study design, population, sex, sarcopenia definition, continent, and study quality.

This is the first meta‐analysis examining the association between sarcopenia, falls, and fractures among older adults including various definitions of sarcopenia. A meta‐analysis[76](#jcsm12411-bib-0076){ref-type="ref"} published in 2004 showed a positive association between muscle strength and falls; since then, the literature has expanded substantially. A previous systematic review assessing various health outcomes of sarcopenia showed positive associations but was based on the EWGSOP definition only.[14](#jcsm12411-bib-0014){ref-type="ref"} A recently published meta‐analysis (9 studies)[77](#jcsm12411-bib-0077){ref-type="ref"} has found a significant association between sarcopenia and fractures with a smaller pooled effect size (risk ratio 1.34) compared with the subgroup analysis for community‐dwelling older adults (OR: 1.73, 95% CI: 1.50--2.00) in our meta‐analysis. The previous study included only prospective studies in community‐dwelling older adults aged 60 years, which contrasts our review addressing both prospective studies and cross‐sectional studies in adults aged 65 years and older.

Evidence was found for both cross‐sectional and prospective studies, implying the existence of different directions of causal pathways, that is, sarcopenia as a cause for falls and fractures, and falls and fractures as a cause for sarcopenia. Falls and fractures can result in loss of mobility, fear of falling, and hospital admissions.[78](#jcsm12411-bib-0078){ref-type="ref"} Physical inactivity associated with these consequences accelerates loss of muscle mass and muscle strength.[79](#jcsm12411-bib-0079){ref-type="ref"} This may explain the results from cross‐sectional studies in which sarcopenic individuals had higher risk of retrospective falls and fractures compared with non‐sarcopenic individuals. On the other hand, impaired standing balance is a strong risk factor for falls.[80](#jcsm12411-bib-0080){ref-type="ref"} The ability to maintain balance requires interaction of motor (muscle), nervous, and sensory systems.[81](#jcsm12411-bib-0081){ref-type="ref"} Muscle strength and muscle mass have been shown to be positively associated with the ability to maintain standing balance in older adults,[15](#jcsm12411-bib-0015){ref-type="ref"}, [82](#jcsm12411-bib-0082){ref-type="ref"} which may explain the positive associations between sarcopenia and falls/fractures in the prospective studies.

Most of the studies included in this systematic review and meta‐analysis were conducted among community‐dwelling individuals. Three included studies examined the association between sarcopenia and falls among nursing home residents[33](#jcsm12411-bib-0033){ref-type="ref"}, [37](#jcsm12411-bib-0037){ref-type="ref"}, [74](#jcsm12411-bib-0074){ref-type="ref"} and one study among hospitalized patients,[43](#jcsm12411-bib-0043){ref-type="ref"} but no associations were found. In these specific populations, sarcopenia as a risk for falls may be overshadowed by other high prevalent risk factors such as the number of diseases, urinary incontinence, polypharmacy, and antidepressant use.[83](#jcsm12411-bib-0083){ref-type="ref"}

Sarcopenia is mainly prevalent in older adults compared with younger ages, where disease pathology is likely to be different. Muscle mass loss is multifactorial. Lifestyle behaviours such as physical inactivity and poor diet are important contributors to the loss of muscle mass and strength at any age, and also, genetic contributions have been described.[84](#jcsm12411-bib-0084){ref-type="ref"} With the aging process, other contributing factors include state of chronic inflammation,[85](#jcsm12411-bib-0085){ref-type="ref"} functional and structural decline of the neuromuscular systems, lower muscle turnover and repair capacity due to decreased muscle protein synthesis, and altered endocrine function.[86](#jcsm12411-bib-0086){ref-type="ref"}, [87](#jcsm12411-bib-0087){ref-type="ref"}, [88](#jcsm12411-bib-0088){ref-type="ref"}, [89](#jcsm12411-bib-0089){ref-type="ref"}, [90](#jcsm12411-bib-0090){ref-type="ref"}

Our study showed that the positive association between sarcopenia with falls and fractures was independent of most of the applied sarcopenia definitions. However, using the EWGSOP and IWGS definitions, which include low physical performance and/or grip strength in addition to low muscle mass in their diagnostic algorithm,[24](#jcsm12411-bib-0024){ref-type="ref"} higher risks of falls and fractures among sarcopenic individuals compared with non‐sarcopenic individuals were shown. This indicates that low muscle function has an additional role in the association with falls and fractures compared with muscle mass alone. Cross‐sectional analysis among 3493 non‐institutionalized older adults found that low muscle mass and low muscle function are independent risk factors for losing physical independence in later life. However, individuals with both low muscle mass and low muscle function presented the highest risk for losing physical independence.[91](#jcsm12411-bib-0091){ref-type="ref"} In addition, a prospective study suggested that muscle strength rather than muscle mass at baseline was associated with increased falls risk score and fracture incidence at 10 years follow‐up in community‐dwelling older adults.[92](#jcsm12411-bib-0092){ref-type="ref"}

This highlights the importance of muscle strength or physical performance in the sarcopenia definition, in line with current definitions.[58](#jcsm12411-bib-0058){ref-type="ref"}, [59](#jcsm12411-bib-0059){ref-type="ref"}, [61](#jcsm12411-bib-0061){ref-type="ref"}, [62](#jcsm12411-bib-0062){ref-type="ref"}, [68](#jcsm12411-bib-0068){ref-type="ref"}, [93](#jcsm12411-bib-0093){ref-type="ref"} However, literatures also showed the value of including muscle mass in sarcopenia definitions. Muscle mass but not muscle strength or physical performance was associated with bone mineral density[94](#jcsm12411-bib-0094){ref-type="ref"} and insulin resistance.[95](#jcsm12411-bib-0095){ref-type="ref"} This reflects the complex role of muscle as not only a strength generator but also an important organ performing protein storage, glucose regulation, hormone production, and other cellular mechanisms.[96](#jcsm12411-bib-0096){ref-type="ref"} A discussion on the use of a single diagnostic criterion or a combination of diagnostic criteria for sarcopenia should take into account which criterion has the strongest predictive value on clinical outcomes.

High heterogeneity was found for the association between sarcopenia and fractures. This heterogeneity can largely be attributed to one specific study, which included a combination of 359 hospitalized patients with fracture and 1614 community‐dwelling older individuals as control group in the same study population.[51](#jcsm12411-bib-0051){ref-type="ref"} In that study, the hospitalized patients were older than the control group. Because the prevalence of sarcopenia is higher with age,[97](#jcsm12411-bib-0097){ref-type="ref"} the association between sarcopenia and fractures may be overestimated, which is further underpinned by a high crude OR of the association between sarcopenia and fractures. Note that the association between sarcopenia and fractures remained significant after excluding aforementioned study from the meta‐analysis.

Clinical implications {#jcsm12411-sec-0015}
---------------------

The robust outcome from our meta‐analysis that sarcopenic individuals have a significantly higher risk of falls and fractures compared with non‐sarcopenic individuals stresses the urgency for timely diagnosis and treatment of sarcopenia as a modifiable risk factor for falls and fractures. Interventions aimed at slowing down the decline of muscle mass and muscle strength and at treating sarcopenia should be considered. Current evidence suggests that progressive resistance training improves risk factors for falls and fractures such as muscle function, balance, and functional mobility.[16](#jcsm12411-bib-0016){ref-type="ref"} However, it is unclear if the effect of progressive resistance training translates directly into a reduction in incidence of falls and fractures.[98](#jcsm12411-bib-0098){ref-type="ref"} Further randomized controlled trials examining the effect of progressive resistance training on falls and fractures outcomes are warranted.

Strengths and limitations {#jcsm12411-sec-0016}
-------------------------

In the absence of an international consensus definition of sarcopenia, we included studies with different diagnostic criteria of sarcopenia. In cases of missing data, we contacted authors of studies to obtain the data needed to compute ORs.

A limitation of the present review was that results of the included studies were expressed as crude as well as adjusted ORs with varying adjustments. The inconsistency in reporting effect size might have either overestimated or underestimated the overall association of interest. In addition, most of the studies included in the systematic review and meta‐analysis were conducted among community‐dwelling individuals and a limited number of institutionalized individuals. Subgroup analysis by continent was conducted instead of ethnicity because data stratified by ethnicity was not available.

Conclusions {#jcsm12411-sec-0017}
===========

This systematic review and meta‐analysis highlights the positive association between sarcopenia, falls, and fractures. These findings are independent of study design, population, sex, sarcopenia definition, continent, and study quality. This strengthens the need to invest in studies evaluating sarcopenia prevention and intervention programmes on its effect on falls and fractures.
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